About Regeneus
Regeneus is an Australian biotechnology company aiming to improve the quality of life of patients suffering from pain.
We develop regenerative medicine products that interrupt the inflammatory cascade that leads to pain in the first place. Worldwide, there are hundreds of millions of patients suffering from short-term and chronic pain. Regeneus listed on the Australian Securities Exchange (ASX) in September 2013 under the ticker code ‘RGS’.
Investment highlight
Regeneus is focused on the US$69 billion global pain market, starting with commercialising Progenza for osteoarthritis in Japan
Latest news & insights
See below for the latest updates on the Company's activity.
Company update and season’s greetings from Regeneus
Regeneus CEO Karolis Rosickas shares a company update as we look ahead to 2021.
2020 Annual General Meeting – Recording
Regeneus (ASX:RGS) held its 2020 Annual General Meeting on Wednesday 14 October, 2020 at 2:30pm.
For shareholders that missed it, you can listen to the recording below, and refer to the Results of Annual General Meeting ASX announcement here.
Regeneus CEO Leo Lee with Proactive at the ASX Small and Mid-Cap Conference 2020
Regeneus CEO Leo Lee speaks to Proactive Investors' Andrew Scott while at the virtual ASX Small and Mid-Cap Conference 2020. During the interview, Leo talks about how Regeneus is working towards its mission to improve the quality of life for patients suffering from pain through their regenerative medicine products Progenza™ and Sygenus, the recent deal with Japanese manufacturing giant Kyocera Corporation, the experience of Regeneus' Board, and the current opportunity for investors.
Watch Leo's full interview with Proactive Investors here.
Subscribe to our investor newsletter
Subscribe to Regeneus' investor newsletter for the latest information and updates